MA46325A - Composés dinucléotidiques cycliques - Google Patents
Composés dinucléotidiques cycliquesInfo
- Publication number
- MA46325A MA46325A MA046325A MA46325A MA46325A MA 46325 A MA46325 A MA 46325A MA 046325 A MA046325 A MA 046325A MA 46325 A MA46325 A MA 46325A MA 46325 A MA46325 A MA 46325A
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- dinucleotidic
- cyclic
- groups
- general formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne des composés de formule générale i, (i), dans laquelle les groupes r 1 , r 2 et r 3 sont tels que définis dans la revendication 1, qui présentent des propriétés pharmacologiques intéressantes, en particulier des modulateurs de sting.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16191919 | 2016-09-30 | ||
| PCT/EP2017/074608 WO2018060323A1 (fr) | 2016-09-30 | 2017-09-28 | Composés dinucléotidiques cycliques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA46325A true MA46325A (fr) | 2019-08-07 |
| MA46325B1 MA46325B1 (fr) | 2021-02-26 |
Family
ID=57103851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA46325A MA46325B1 (fr) | 2016-09-30 | 2017-09-28 | Composés dinucléotidiques cycliques |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US10537590B2 (fr) |
| EP (1) | EP3519420B1 (fr) |
| JP (1) | JP6509445B2 (fr) |
| KR (2) | KR102536447B1 (fr) |
| CN (1) | CN109843903B (fr) |
| AR (1) | AR109777A1 (fr) |
| AU (1) | AU2017333933B2 (fr) |
| CA (1) | CA3038860C (fr) |
| CL (1) | CL2019000775A1 (fr) |
| CO (1) | CO2019003178A2 (fr) |
| CY (1) | CY1124638T1 (fr) |
| DK (1) | DK3519420T3 (fr) |
| EA (1) | EA037030B1 (fr) |
| ES (1) | ES2848724T3 (fr) |
| HR (1) | HRP20210027T1 (fr) |
| HU (1) | HUE053819T2 (fr) |
| IL (1) | IL265642B (fr) |
| JO (1) | JOP20190066B1 (fr) |
| LT (1) | LT3519420T (fr) |
| MA (1) | MA46325B1 (fr) |
| MX (1) | MX2019003586A (fr) |
| MY (1) | MY200083A (fr) |
| NZ (1) | NZ750906A (fr) |
| PE (1) | PE20191503A1 (fr) |
| PH (1) | PH12019500706B1 (fr) |
| PL (1) | PL3519420T3 (fr) |
| PT (1) | PT3519420T (fr) |
| RS (1) | RS61423B1 (fr) |
| SA (1) | SA519401435B1 (fr) |
| SI (1) | SI3519420T1 (fr) |
| TW (1) | TWI774697B (fr) |
| UA (1) | UA124347C2 (fr) |
| WO (1) | WO2018060323A1 (fr) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL280430B2 (en) | 2016-03-18 | 2023-11-01 | Univ Texas | Cyclic dinucleotide compounds and methods of use |
| EP3507367A4 (fr) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| WO2018100558A2 (fr) | 2016-12-01 | 2018-06-07 | Takeda Pharmaceutical Company Limited | Dinucléotide cyclique |
| EP3824906A1 (fr) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Formulations d'anticorps anti-tnf alpha |
| US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
| JP7160833B2 (ja) | 2017-04-13 | 2022-10-25 | サイロパ ビー.ブイ. | 抗sirpアルファ抗体 |
| WO2018195450A1 (fr) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Thérapies d'association avec des inhibiteurs d'ehmt2 |
| TWI808092B (zh) | 2017-08-30 | 2023-07-11 | 中國大陸商北京軒義醫藥科技有限公司 | 作為干擾素基因調節劑之刺激劑的環狀二核苷酸 |
| WO2019084060A1 (fr) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | Conjugués et leurs procédés d'utilisation pour l'administration sélective d'agents immunomodulateurs |
| PH12020550585A1 (en) | 2017-11-10 | 2021-04-19 | Takeda Pharmaceuticals Co | Sting modulator compounds, and methods of making and using |
| US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| JP7037667B2 (ja) | 2017-12-20 | 2022-03-16 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | Stingアダプタータンパク質を活性化するホスホン酸結合を有する3’3’環状ジヌクレオチド |
| US12220462B1 (en) | 2018-02-13 | 2025-02-11 | Abionyx Pharma Sa | Complexes for delivery of cyclic dinucleotides |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ, インコーポレイテッド | Hbv複製阻害剤としての置換ピロリジン化合物 |
| US20210024567A1 (en) * | 2018-03-27 | 2021-01-28 | Boehringer Ingelheim International Gmbh | Modified cyclic dinucleotide compounds |
| WO2019195181A1 (fr) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Anticorps et leurs fragments qui se lient à la protéine x du virus de l'hépatite b |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| WO2019211799A1 (fr) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Analogue de dinucléotide 2'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle |
| EP3802534B1 (fr) | 2018-05-25 | 2022-07-13 | Incyte Corporation | Composés hétérocycliques tricycliques en tant qu'activateurs de sting |
| US10875872B2 (en) | 2018-07-31 | 2020-12-29 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
| WO2020028565A1 (fr) | 2018-07-31 | 2020-02-06 | Incyte Corporation | Composés hétéroaryles tricycliques en tant qu'activateurs de sting |
| WO2020028097A1 (fr) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Formes solides d'acide (r)-11-(méthoxyméthyl)-12-(3-méthoxypropoxy)-3,3-diméthyl-8-0 x0-2,3,8,13b-tétrahydro-1h-pyrido[2,1-a] pyrrolo[1,2-c]phtalazine-7-carboxylique |
| KR102783784B1 (ko) | 2018-08-16 | 2025-03-21 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 화합물의 염 및 이의 결정 |
| CN118846110A (zh) | 2018-09-06 | 2024-10-29 | 第一三共株式会社 | 抗体药物偶联物 |
| SG11202101980VA (en) | 2018-09-12 | 2021-03-30 | Silverback Therapeutics Inc | Methods and composition for the treatment of disease with immune stimulatory conjugates |
| MA53659A (fr) | 2018-09-21 | 2022-02-23 | Shanghai De Novo Pharmatech Co Ltd | Analogue dinucléotidique cyclique, composition pharmaceutique associée et utilisation |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EP3873484B1 (fr) | 2018-10-29 | 2023-08-23 | Venenum Biodesign, LLC | Nouveaux agonistes de sting |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| EP3873608A1 (fr) | 2018-10-31 | 2021-09-08 | Gilead Sciences, Inc. | Composés 6-azabenzimidazole substitués ayant une activité inhibitrice de hpk1 |
| EP4371987B9 (fr) | 2018-10-31 | 2025-11-26 | Gilead Sciences, Inc. | Composés de 6-azabenzimidazole substitués utilisés en tant qu'inhibiteurs de hpk1 |
| US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
| WO2020146237A1 (fr) | 2019-01-07 | 2020-07-16 | Incyte Corporation | Composés d'amide d'hétéroaryle en tant qu'activateurs de sting |
| CN113574063B (zh) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 3’3’-环二核苷酸及其前药 |
| WO2020178768A1 (fr) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Analogue du dinucléotide 3'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle utilisé en tant que modulateur de sting |
| WO2020178769A1 (fr) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Dinucléotides cycliques en 2'3' et leurs promédicaments |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| CN114127082A (zh) | 2019-05-09 | 2022-03-01 | 阿里戈斯治疗公司 | 作为sting调节剂的经修饰的环状二核苷化合物 |
| TWI925817B (zh) | 2019-05-10 | 2026-05-21 | 日商武田藥品工業股份有限公司 | 抗體藥物結合物 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| CN114245807B (zh) | 2019-06-25 | 2025-05-02 | 吉利德科学公司 | Flt3l-fc融合蛋白和使用方法 |
| WO2021007160A1 (fr) | 2019-07-05 | 2021-01-14 | Tambo, Inc. | Agents bioorthogonaux de trans-cyclooctène et leurs utilisations dans le traitement du cancer et l'immunothérapie |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| HRP20241379T1 (hr) | 2019-09-30 | 2024-12-20 | Gilead Sciences, Inc. | Cjepiva za hbv i postupci za liječenje hbv |
| WO2021067644A1 (fr) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Polythérapie comprenant des conjugués immunostimulants |
| US12410418B2 (en) | 2019-12-06 | 2025-09-09 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| US12678512B2 (en) | 2020-03-06 | 2026-07-14 | Daiichi Sankyo Company, Limited | Anti-EGFR antibody-drug conjugate with a cyclic dinucleotide derivative |
| KR102987126B1 (ko) | 2020-03-20 | 2026-07-07 | 길리애드 사이언시즈, 인코포레이티드 | 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법 |
| US20230141284A1 (en) | 2020-04-10 | 2023-05-11 | Ono Pharmaceutical Co., Ltd. | Cancer therapeutic method |
| JP2023504675A (ja) | 2020-05-19 | 2023-02-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ガンの処置のための結合分子 |
| KR20230047361A (ko) | 2020-07-01 | 2023-04-07 | 아르스 파마슈티컬스 인크. | 항-asgr1 항체 접합체 및 이의 용도 |
| LT4192474T (lt) | 2020-08-07 | 2025-11-25 | Fosfonamidų nukleotidų analogų provaistai ir jų farmacinis panaudojimas | |
| JP2023537066A (ja) | 2020-08-07 | 2023-08-30 | タンボ・インコーポレイテッド | トランス-シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用 |
| EP4209506A4 (fr) | 2020-09-02 | 2024-10-09 | Daiichi Sankyo Company, Limited | Nouvelle endo-?-n-acétylglucosaminidase |
| WO2022079175A1 (fr) | 2020-10-14 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Association d'un agoniste de sting et d'un complexe comprenant un peptide de pénétration cellulaire, une cargaison et un agoniste peptidique de tlr |
| JP7875196B2 (ja) | 2020-10-20 | 2026-06-17 | タイリガンド バイオサイエンス(シャンハイ)リミテッド | 多機能環状ジヌクレオチド及びその使用 |
| JP7397996B2 (ja) | 2020-11-09 | 2023-12-13 | 武田薬品工業株式会社 | 抗体薬物コンジュゲート |
| TW202241454A (zh) | 2021-02-01 | 2022-11-01 | 日商第一三共股份有限公司 | 抗體-免疫賦活化劑共軛物之新穎製造方法 |
| US20240269142A1 (en) | 2021-05-13 | 2024-08-15 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| WO2022245671A1 (fr) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Méthodes d'utilisation de protéines de fusion flt3l-fc |
| EP4359413A1 (fr) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Composés de modulation de la diacylglycérol kinase |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ, インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| IL315341A (en) | 2022-03-02 | 2024-10-01 | Daiichi Sankyo Co Ltd | METHOD FOR PRODUCING Fc-CONTAINING MOLECULE |
| KR20250054799A (ko) | 2022-08-29 | 2025-04-23 | 다이이찌 산쿄 가부시키가이샤 | 변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트 |
| TW202608468A (zh) | 2024-05-13 | 2026-03-01 | 美商基利科學股份有限公司 | 組合療法 |
| US20250345390A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240246A1 (fr) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Polythérapies avec de la ribavirine |
| WO2025240242A1 (fr) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Polythérapies avec ribavirine |
| DE212025000115U1 (de) | 2024-07-30 | 2026-06-18 | Sairopa B.V. | Anti-SIRP Alpha-Antikörperformulierungen und ihre Verwendung |
| CN119930724B (zh) * | 2024-12-18 | 2025-10-28 | 湖南大学 | 一种诱导激活的自递送环二核苷衍生物及其制备方法与用于抗肿瘤免疫治疗的用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE478886T1 (de) * | 2003-07-25 | 2010-09-15 | Idenix Pharmaceuticals Inc | Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c |
| US7592326B2 (en) | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
| WO2005089777A1 (fr) * | 2004-03-15 | 2005-09-29 | Karaolis David K R | Procede inhibant la proliferation et accroissant l'apoptose de cellules cancereuses |
| WO2010098788A2 (fr) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Antagonistes de pd-i et procédés de traitement d'une maladie infectieuse |
| EP2504028A4 (fr) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | Inhibition simultanée de pd-l1/pd-l2 |
| CA2804550C (fr) | 2010-07-09 | 2021-01-05 | Bionovion Holding B.V. | Anticorps agoniste de cd27 |
| SG11201502796RA (en) | 2012-12-13 | 2015-05-28 | Aduro Biotech Inc | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| JP2016506408A (ja) | 2012-12-19 | 2016-03-03 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 哺乳動物の環状ジヌクレオチドシグナル伝達経路の薬学的標的化 |
| CN105377867B (zh) | 2013-05-03 | 2019-11-12 | 加利福尼亚大学董事会 | I型干扰素的环状二核苷酸诱导 |
| CU24377B1 (es) | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
| US10176292B2 (en) | 2013-07-31 | 2019-01-08 | Memorial Sloan-Kettering Cancer Center | STING crystals and modulators |
| PL3099717T3 (pl) | 2014-01-31 | 2019-10-31 | Novartis Ag | Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie |
| EA201691765A1 (ru) | 2014-03-14 | 2016-12-30 | Новартис Аг | Молекулы антител против lag-3 и их применения |
| EP3152217B1 (fr) | 2014-06-04 | 2018-08-01 | GlaxoSmithKline Intellectual Property Development Limited | Di-nucléotides cycliques utilisés comme modulateurs de sting |
| DK3233882T3 (da) | 2014-12-16 | 2020-01-27 | Kayla Therapeutics | Fluorinerede cykliske dinukleotider til cytokininduktion |
| GB201501462D0 (en) * | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| TWI706958B (zh) | 2015-03-10 | 2020-10-11 | 美商艾杜諾生物科技公司 | 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法 |
| CN108137641B (zh) | 2015-08-13 | 2022-04-01 | 默沙东公司 | 作为sting激动剂的环状双核苷酸化合物 |
-
2017
- 2017-09-27 US US15/716,720 patent/US10537590B2/en active Active
- 2017-09-28 KR KR1020197012683A patent/KR102536447B1/ko active Active
- 2017-09-28 MY MYPI2019000587A patent/MY200083A/en unknown
- 2017-09-28 HR HRP20210027TT patent/HRP20210027T1/hr unknown
- 2017-09-28 ES ES17772731T patent/ES2848724T3/es active Active
- 2017-09-28 AU AU2017333933A patent/AU2017333933B2/en active Active
- 2017-09-28 DK DK17772731.0T patent/DK3519420T3/da active
- 2017-09-28 SI SI201730631T patent/SI3519420T1/sl unknown
- 2017-09-28 CA CA3038860A patent/CA3038860C/fr active Active
- 2017-09-28 MX MX2019003586A patent/MX2019003586A/es unknown
- 2017-09-28 PH PH1/2019/500706A patent/PH12019500706B1/en unknown
- 2017-09-28 RS RS20210104A patent/RS61423B1/sr unknown
- 2017-09-28 UA UAA201904428A patent/UA124347C2/uk unknown
- 2017-09-28 JP JP2018530574A patent/JP6509445B2/ja active Active
- 2017-09-28 EP EP17772731.0A patent/EP3519420B1/fr active Active
- 2017-09-28 KR KR1020227019917A patent/KR20220084206A/ko not_active Withdrawn
- 2017-09-28 HU HUE17772731A patent/HUE053819T2/hu unknown
- 2017-09-28 PT PT177727310T patent/PT3519420T/pt unknown
- 2017-09-28 WO PCT/EP2017/074608 patent/WO2018060323A1/fr not_active Ceased
- 2017-09-28 NZ NZ750906A patent/NZ750906A/en unknown
- 2017-09-28 EA EA201990785A patent/EA037030B1/ru not_active IP Right Cessation
- 2017-09-28 PL PL17772731T patent/PL3519420T3/pl unknown
- 2017-09-28 PE PE2019000722A patent/PE20191503A1/es unknown
- 2017-09-28 CN CN201780064246.7A patent/CN109843903B/zh active Active
- 2017-09-28 JO JOP/2019/0066A patent/JOP20190066B1/ar active
- 2017-09-28 MA MA46325A patent/MA46325B1/fr unknown
- 2017-09-28 LT LTEP17772731.0T patent/LT3519420T/lt unknown
- 2017-09-29 AR ARP170102737A patent/AR109777A1/es not_active Application Discontinuation
- 2017-09-29 TW TW106133691A patent/TWI774697B/zh active
-
2019
- 2019-03-25 CL CL2019000775A patent/CL2019000775A1/es unknown
- 2019-03-26 IL IL265642A patent/IL265642B/en unknown
- 2019-03-27 SA SA519401435A patent/SA519401435B1/ar unknown
- 2019-03-29 CO CONC2019/0003178A patent/CO2019003178A2/es unknown
-
2021
- 2021-02-08 CY CY20211100105T patent/CY1124638T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46325B1 (fr) | Composés dinucléotidiques cycliques | |
| BR112019022518A2 (pt) | Composto de dinucleotídeo cíclico bis 2'-5'-rr-(3'f-a)(3'f-a) e usos do mesmo | |
| EA201790806A1 (ru) | Иммунорегулирующие средства | |
| MA60161B1 (fr) | Compositions et méthodes pour moduler l'expression de hbv et de ttr | |
| EA201892123A1 (ru) | 6-гидрокси-4-оксо-1,4-дигидропиримидин-5-карбоксамиды в качестве агонистов apj | |
| EA201890858A1 (ru) | 2,4-дигидроксиникотинамиды как агонисты apj | |
| BR112018013820A2 (pt) | análogos de egf(a) com substituintes de ácido graxo | |
| MA43409B1 (fr) | Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton | |
| MX389724B (es) | Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo | |
| MX391221B (es) | Compuestos y composiciones y usos de los mismos. | |
| EA201892500A1 (ru) | Применение фракции лигнина в качестве антифитопатогенного агента и содержащие ее антифитопатогенные композиции | |
| MA39337B1 (fr) | Modulateurs de pyrazines de gpr6 | |
| EA202092695A1 (ru) | Композиции, содержащие глюкозу и гемицеллюлозу, и их применение | |
| MA40366A (fr) | Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines | |
| MA38798A1 (fr) | Imidazothia(dia)zole sulfonamides utilisés en tant que nématicides | |
| MY191993A (en) | Use of isolated fractions of mastic gum for treating optic neuropathy | |
| FR3038609B1 (fr) | Nouveaux hydrogels de structure silylee et procede d'obtention | |
| EA201991850A1 (ru) | Материалы и способы для снижения вязкости нефти | |
| FR3029910B1 (fr) | Nouveaux composes 1-phenyl mono ou polyhydroxypropane, compositions et utilisation en cosmetique | |
| FR3029911B1 (fr) | Nouveaux composes 1,2-diphenylethylene glycol pour lutter contre le vieillissement cutane et utilisation en cosmetique | |
| PL431762A1 (pl) | Sposób wytwarzania (-)-izomeru-(3S)-3-n-butyloftalidu | |
| MA39670B1 (fr) | Biofilm à base de biopolymère modifié et propriétés antibactériennes et fluorescentes. | |
| MA54520B1 (fr) | Composés anticancéreux | |
| EA201991653A1 (ru) | Изоляты bacillus и варианты их применения | |
| UA119230U (uk) | Квас слабоалкогольний |